The FDA Grants Thermo (NYSE: TMO) Fisher Approval

The FDA’s approval of Thermo Fisher’s Oncomine Dx Target Test for zongertinib in non-small cell lung cancer with HER2 mutations represents a significant advancement in targeted cancer care.

Notably, the regulatory agency approved Hernexeos — a tyrosine kinase inhibitor — treatment for people with unresectable or metastatic non-squamous NSCLC whose tumors have HER2 tyrosine kinase domain (TKD) activating mutations on August 8, 2025.